Objective: Although beta-amyloid (Aβ) positron emission tomography (PET) images are interpreted visually as positive or negative, approximately 10% are judged as equivocal in Alzheimer\u27s disease. Therefore, we aimed to develop an automated semi-quantitative analysis technique using 18F-flutemetamol PET images without anatomical images.Methods: Overall, 136 cases of patients administered 18F-flutemetamol were enrolled. Of 136 cases, five PET images each with the highest and lowest values of standardized uptake value ratio (SUVr) of cerebral cortex-to-pons were used to create positive and negative templates. Using these templates, PET images of the remaining 126 cases were standardized, and SUVr images were produced with the pons as a refe...
Positron emission tomography (PET) allows for in vivo visualisation and quantification of amyloid-β ...
BACKGROUND AND PURPOSE: While AD can be definitively confirmed by postmortem histopathologic examina...
Our objective was to determine the optimal approach for assessing amyloid disease in a cognitively n...
Background: Quantitative evaluation of amyloid positron emission tomography(PET) with standardized u...
Background: 18F-flutemetamol positron emission tomography (PET) is used to assess cortical amyloid-β...
Objective: Visual evaluation is the standard for amyloid positron emission tomography (PET) examinat...
Clinical trials of the PET amyloid imaging agent 18F-flutemetamol have used visual assessment to cla...
Clinical trials of the PET amyloid imaging agent 18F-flutemetamol have used visual assessment to cla...
Alzheimer’s disease (AD) is the leading cause of dementia and is alone responsible for 60-70% of all...
Background: Amyloid PET plays a vital role in detecting the accumulation of in vivo amyloid-β (Aβ). ...
Abstract: Our objective was to determine the optimal approach for assessing amyloid disease in a cog...
Alzheimer’s disease (AD) is the leading cause of dementia and is alone responsible for 60-70% of all...
Alzheimer’s disease (AD) is the leading cause of dementia and is alone responsible for 60-70% of all...
Alzheimer’s disease (AD) is the leading cause of dementia and is alone responsible for 60-70% of all...
Alzheimer’s disease (AD) is the leading cause of dementia and is alone responsible for 60-70% of all...
Positron emission tomography (PET) allows for in vivo visualisation and quantification of amyloid-β ...
BACKGROUND AND PURPOSE: While AD can be definitively confirmed by postmortem histopathologic examina...
Our objective was to determine the optimal approach for assessing amyloid disease in a cognitively n...
Background: Quantitative evaluation of amyloid positron emission tomography(PET) with standardized u...
Background: 18F-flutemetamol positron emission tomography (PET) is used to assess cortical amyloid-β...
Objective: Visual evaluation is the standard for amyloid positron emission tomography (PET) examinat...
Clinical trials of the PET amyloid imaging agent 18F-flutemetamol have used visual assessment to cla...
Clinical trials of the PET amyloid imaging agent 18F-flutemetamol have used visual assessment to cla...
Alzheimer’s disease (AD) is the leading cause of dementia and is alone responsible for 60-70% of all...
Background: Amyloid PET plays a vital role in detecting the accumulation of in vivo amyloid-β (Aβ). ...
Abstract: Our objective was to determine the optimal approach for assessing amyloid disease in a cog...
Alzheimer’s disease (AD) is the leading cause of dementia and is alone responsible for 60-70% of all...
Alzheimer’s disease (AD) is the leading cause of dementia and is alone responsible for 60-70% of all...
Alzheimer’s disease (AD) is the leading cause of dementia and is alone responsible for 60-70% of all...
Alzheimer’s disease (AD) is the leading cause of dementia and is alone responsible for 60-70% of all...
Positron emission tomography (PET) allows for in vivo visualisation and quantification of amyloid-β ...
BACKGROUND AND PURPOSE: While AD can be definitively confirmed by postmortem histopathologic examina...
Our objective was to determine the optimal approach for assessing amyloid disease in a cognitively n...